消旋蜂蜜曲菌素 | 1200-93-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 消旋蜂蜜曲菌素
• 中文别名: (±)-3,4-二氢-8-羟基-3-甲基-2-苯并吡喃-1-酮；蜂蜜曲菌素
• 英文名称: mellein
• 英文别名: 8-hydroxy-3-methyl-3,4-dihydroisochromen-1-one
• CAS: 1200-93-7
• 化学式: C₁₀H₁₀O₃
• mdl: MFCD00142319
• 分子量: 178.188
• InChiKey: KWILGNNWGSNMPA-UHFFFAOYSA-N

物化性质

• 熔点：
  37-39 °C
• 沸点：
  392.7±42.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Predicted)
• 保留指数：
  2432

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S22,S24/25
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  消旋蜂蜜曲菌素 在 palladium on activated charcoal 重铬酸吡啶 、 氨 、 氢气 、 lithium 、 叔丁醇 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， -78.0 ℃ 、101.33 kPa 条件下， 生成 ramulosin
  参考文献：
  名称：

  Birch reduction of 3,4-dihydro-8-hydroxy-3-methylisocoumarin (mellein). Expeditious syntheses of (±)-ramulosin and a spruce budworm toxin

  摘要：

  A three-step conversion of (+/-)-mellein (1) to (+/-)-ramulosin (6) in 41% overall yield is described. A synthesis of the spruce budworm toxin 7 also is reponed. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)00296-7
• 作为产物：
  描述：

  mellein methyl ether 在 三氯化硼 作用下， 以 二氯甲烷 为溶剂， 以87%的产率得到消旋蜂蜜曲菌素
  参考文献：
  名称：

  苯甲酸的区域专一性邻位-CH烯丙基化

  摘要：

  已经开发出了一种羧酸盐定向的邻-CH功能基，可以将烯丙基残基的区域特异性引入苯甲酸中。在[Ru（p- cymene）Cl 2 ] 2和K 3 PO 4存在下，苯甲酸在仅50°C的条件下与乙酸烯丙酯反应，生成相应的邻-烯丙基苯甲酸。该方案通常适用于富电子和贫电子的苯甲酸与直链和支链乙酸烯丙酯的组合。可以通过双键迁移，内酯化或脱羧等方法在原位进一步对产品进行功能化。

  DOI：

  10.1002/anie.201712520

文献信息

• On the role of copper and iron in DNA cleavage by ochratoxin A. Structure-activity relationships in metal binding and copper-mediated DNA cleavage
  作者：Jason A Ardus、Ivan G Gillman、Richard A Manderville

  DOI：10.1139/v98-088

  日期：1998.6.1

  Ochratoxin A (OTA, 1: X = Cl) is a fungal carcinogen that facilitates single-strand DNA cleavage and DNA adduction when metabolically activated. To determine if redox-active transition metals induce OTA-mediated DNA damage, we have examined the toxin's ability to bind Cu(II) and Fe(III) in aqueous media and facilitate DNA cleavage in their presence using agarose gel electrophoresis and supercoiled plasmid DNA. Using fluorescence spectroscopy, 1 was found to bind Cu(II) readily at physiological pH, while acidic conditions (pH 2.6) were employed to study Fe(III) binding due to the formation of Fe-oxide precipitates at higher pH values. Structure-activity relationships employing synthetic derivatives of 1 implied that 1 binds both Cu(II) and Fe(III) by its phenolic oxygen, while the carboxylic acid of its phenylalanine moiety binds Cu(II), but does not appear to play a role in Fe(III) coordination at pH 2.6. In terms of metal-mediated DNA cleavage, no role for 1 could be detected in Fe-induced DNA strand scission. With Cu(II), DNA cleavage by the 1:1 copper-bound complex of 1 could only be initiated by addition of a suitable reducing agent (sodium ascorbate). However, 1 was found to facilitate DNA cleavage by the Cu(II) complex of 1,10-phenanthroline (Cu(OP)₂); a prototypical Cu-mediated nuclease system that cleaves DNA upon activation by an external reducing agent. Structure-activity relationships employing analogs lacking the chlorine atom, ochratoxin B (2: X = H), and the lactone (12), indicated that the chlorine atom is essential for activity of the OTA in potentiating DNA cleavage by Cu(OP)₂. The implications of our findings to the genotoxic properties of 1 are discussed.Key words: ochratoxin, DNA cleavage, copper, iron, 1,10-phenanthroline.

  奥克拉毒素A（OTA，1：X = Cl）是一种真菌致癌物质，当在代谢活化时，它促进单链DNA断裂和DNA加合物的形成。为了确定氧化还原活性过渡金属是否诱导OTA介导的DNA损伤，我们研究了毒素在水介质中结合Cu（II）和Fe（III）的能力，并在它们的存在下利用琼脂糖凝胶电泳和超螺旋质粒DNA促进DNA断裂。利用荧光光谱，发现1在生理pH下能够很容易地结合Cu（II），而在酸性条件（pH 2.6）下用于研究Fe（III）结合，因为在较高pH值下会形成Fe-氧化物沉淀。利用1的合成衍生物进行结构活性关系研究表明，1通过其酚氧结合Cu（II）和Fe（III），而其苯丙氨酸部分的羧酸结合Cu（II），但在pH 2.6下似乎不参与Fe（III）的配位。在金属介导的DNA断裂方面，未发现1在Fe诱导的DNA链切断中起作用。对于Cu（II），只有通过添加适当的还原剂（抗坏血酸钠）才能启动1的1：1铜结合复合物引发的DNA断裂。然而，发现1能够通过1,10-邻菲啰啉（Cu（OP）2）的Cu（II）复合物促进DNA断裂；这是一种原型的Cu介导核酸酶系统，只有在外部还原剂的激活下才能切割DNA。通过缺乏氯原子的类似物进行结构活性关系研究，如奥克拉毒素B（2：X = H）和内酯（12），表明氯原子对于OTA在促进Cu（OP）2介导的DNA断裂中的活性是必不可少的。我们的研究结果对于1的遗传毒性特性的影响进行了讨论。关键词：奥克拉毒素，DNA断裂，铜，铁，1,10-邻菲啰啉。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。
• [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024048A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.

  本发明涉及水溶性载体连接的前药，其化学式为（I），其中POL是聚合物基团，每个Hyp是独立的超支化基团，每个基团SP是独立的间隔基团，每个L是独立的可逆前药连接基团，m为0或1，每个n是独立的整数，范围从2到200，每个x是独立的0或1。此外，还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。
• [EN] HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS HYDROSOLUBLES DE FORTE CHARGE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024047A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independendly a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use asmedicament or diagnostic, and methods of treatment.

  本发明涉及水溶性载体连接的前药，其化学式为(I)，其中B、A和Hyp形成载体，B是一个分支核心，每个A独立地是一条聚乙二醇基聚合链，每个Hyp独立地是一个分支基团，每个SP独立地是一个间隔基团，每个L独立地是一个可逆前药连接基团，每个D独立地是一个生物活性基团，每个x独立地为0或1，每个m独立地是从2到64的整数，n是从3到32的整数；或其药学上可接受的盐。进一步涉及包括所述水溶性载体连接的前药的药物组合物，其用作药物或诊断，以及治疗方法。
• [EN] RELEASABLE CONJUGATES<br/>[FR] CONJUGUÉS LIBÉRABLES
  申请人：QUIAPEG PHARMACEUTICALS AB

  公开号：WO2018163131A1

  公开（公告）日：2018-09-13

  The present application provides compounds of Formula (B), or pharmaceutically acceptable salts thereof, wherein D is a residue of a biologically active drug, which underdo hydrolysis under physiological conditions to release the biologically active drug and which are useful in the treatment of disorders that could be beneficially treated with the drug.

  本申请提供了化合物的公式（B），或其药用盐，其中D是生物活性药物的残留物，在生理条件下经过水解释放出生物活性药物，并且对可能受益于该药物治疗的疾病具有用处。

表征谱图